Silvestrol has shown significant potential in cancer research due to its ability to inhibit protein synthesis in cancer cells. It selectively targets the eukaryotic initiation factor 4A (eIF4A), disrupting the translation of specific mRNAs that are crucial for tumor growth and survival. This mechanism makes it particularly effective against certain types of cancers, such as leukemia, breast cancer, and pancreatic cancer, where these proteins are overexpressed. Additionally, silvestrol has demonstrated antiviral properties, particularly against RNA viruses like Ebola and coronavirus, by interfering with viral replication. Its unique mode of action and selectivity continue to make it a promising candidate for further drug development and therapeutic applications.